Therapeutic Areas
Science of RNAi
Video
RNAi Mechanism of Action
This video highlights the mechanism of action (MOA) of RNAi therapeutics and its role in silencing gene expression. This video is intended to be viewed in its entirety.
Congresses
Primary Hyperoxaluria Type 1 (PH1)
European Renal Association (ERA) 2026
Cardiovascular (CV)
European Renal Association (ERA) 2026
Cardiovascular (CV)
European Society of Hypertension (ESH) 2026
Publications
Transthyretin Amyloidosis (ATTR)
Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis
Clinical Pharmacokinetics
Transthyretin Amyloidosis (ATTR)
Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post-Hoc Analysis of HELIOS-B
JACC: Asia
Transthyretin Amyloidosis (ATTR)
Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B
Journal of Cardiac Failure
Connect with Alnylam Medical
For further information or questions related to Alnylam's clinical data, connect with Alnylam Medical.
Medical Information
For Medical Information inquiries, please submit your question using the email below.
For country-specific Medical Information contact details, please navigate to the individual country sites located at Alnylam.com.
Adverse Events/Product Complaints
To report an adverse event or to submit a product complaint, please use the email below.
For country-specific contact details, please navigate to the individual country sites located at Alnylam.com.
Clinical Trials
For clinical trial inquiries, please use the contact options below.
